While glucagon like peptide 1 receptor agonists (GLP-1 RAs) such as semaglutide have been shown to be effective in promoting weight loss in the general population [6], their application in syndromic obesity, such as that seen in SMS, is still an emerging area of study. This evidence concerns the gene GLP1R and obesity disorder.